41763-92-2

Basic information

• Product Name: 2-(2-cyclohexylethyl)isoindoline-1,3-dione
• Synonyms: 2-(2-cyclohexylethyl)isoindoline-1,3-dione
• CAS NO: 41763-92-2
• Molecular Weight: 257.332
• Mol File: 41763-92-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-(2-cyclohexylethyl)isoindoline-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-cyclohexylethyl)isoindoline-1,3-dione(41763-92-2)
• EPA Substance Registry System: 2-(2-cyclohexylethyl)isoindoline-1,3-dione(41763-92-2)

Safety Data

• Hazardous Substances Data: 41763-92-2(Hazardous Substances Data)

Usage

Physical form

Yellow to brownish powder

Use

Building block in organic synthesis, particularly in the pharmaceutical industry

Potential medical applications

Treatment of various diseases, including cancer and diabetes

Other properties

Antioxidant and anti-inflammatory properties, potential as a photosensitizer in photodynamic therapy for the treatment of skin diseases

Applications

Medical and research fields, due to its unique chemical structure and properties.

Upstream product

• 1647-26-3 1-bromo-2-cyclohexylethane 
• 1074-82-4 potassium phtalimide 
• 136918-14-4 phthalimide 
• 4442-79-9 cyclohexylethan-1-ol 

Downstream Products

• 5471-55-6 2-cyclohexylethan-1-amine hydrochloride 
• 454646-66-3 3-(1H-imidazol-4-yl)propyl 2-cyclohexylethylcarbamate hydrogen maleate 
• 76649-96-2 c-hexylethyl isocyanate 
• 864274-50-0 3-[(2-cyclohexylethyl)amino]-4-nitrobenzonitrile 

Relevant articles and documents

ANTIVIRAL COMPOUNDS AND USE THEREOF

The present invention relates to compounds of formula (I), their use as medicaments, in particular as broad spectrum antiviral agents, their combination with a further antiviral agent and relative pharmaceutical compositions. In particular, the compounds of the invention are useful in the treatment of a disease caused by an enveloped virus.

N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands

Previous studies have shown that several imidazole derivatives posses affinity to histamine H3 and H4 receptors. Continuing our study on structural requirements responsible for affinity and selectivity for H3/H4 receptor subtypes, two series of 3-(1H-imidazol-4-yl)propyl carbamates were prepared: a series of unsaturated alkyl derivatives (1-9) and a series possessing a cycloalkyl group different distances to the carbamate moiety (10-13). The compounds were tested for their affinities at the human histamine H3 receptor, stably expressed in CHO-K1 cells. Compounds 1, 2, 5-7, 10-13 were investigated for their affinities at the human histamine H4 receptor co-expressed with Gαi2 and Gβ1γ2 subunits in Sf9 cells. To expand the pharmacological profile, compounds were further tested for their H3 receptor antagonist activity on guinea pig ileum and in vivo after oral administration to mice. All tested compounds exhibited good affinity for the human histamine H3 receptor with Ki values in the range from 14 to 194 nM. All compounds were active in vivo after peroral administration (p.o.) to Swiss mice, thus demonstrating their ability to cross the blood-brain barrier. The most potent H3 receptor ligand of these series was compound 5, 3-(1H-imidazol-4-yl)propyl pent-4-enylcarbamate with the highest affinity (Ki = 14 nM). Additionally, compound 3 showed remarkable central nervous system (CNS) H3R activity, increasing the Nτ-methylhistamine levels in mice with an ED 50 value of 0.55 mg/kg, p.o. evidencing therefore, a twofold increase of inverse agonist/antagonist potency compared to the reference inverse agonist/antagonist thioperamide. In this study, the imidazole propyloxy carbamate moiety was kept constant. The different lipophilic moieties connected to the carbamate functionality in the eastern part of the molecule had a range of influences on the human H4 receptor affinity (154-1326 nM).

NOVEL CHEMICAL COMPOUNDS

This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.